The U.S. FDA has approved two clinical trials for "aging" as an indication, which function as basket trials for multiple age-related diseases.

Joe Betz-Lacroix predicts that within the next five years, Retro Biosciences will have one approved therapeutic on the market and a total of four therapeutics in human testing.

Retro Biosciences' molecule RTR-242, which is designed to restart the autophagy process in aged neurons, is most of the way through its first clinical trial.

Approximately 85% of all diseases treated in U.S. hospitals are age-related.

Retro Biosciences was seed-funded by Sam Altman and has collaborated with OpenAI to create models that generate novel proteins.

The use of generative AI tools has doubled the day-to-day productivity at Retro Biosciences.